Will CRISPR Therapeutics (CRSP) beat quarterly earnings?: how this market works

What you need to know

This market asks whether CRISPR Therapeutics will lose less money per share than analysts currently expect. The company is not profitable yet, so both outcomes involve a loss. A Yes means the actual loss per share is smaller than $1.18 (for example, a loss of $0.90). A No means the loss is $1.18 or worse (for example, $1.50). It is not about whether the company makes money, just whether it does better or worse than the analyst forecast. The market settles based on the official GAAP earnings per share number CRISPR Therapeutics publishes in its earnings report, expected around August 3, 2026. If that number is greater than negative $1.18, the market resolves Yes. If it is equal to or worse than negative $1.18, it resolves No. One important edge case: if the company delays its report by more than 45 days past August 3, the market automatically resolves No, even without an actual earnings figure. No relevant recent news was provided for this market. The kind of developments worth watching would be any updates on CRISPR Therapeutics' revenue from its gene therapy products, changes in operating expenses, or any company guidance revisions, since those would directly affect whether the actual loss per share comes in better or worse than the $1.18 estimate. The market is roughly split, at 54% Yes, which reflects genuine uncertainty. Biotech companies like CRISPR Therapeutics can have lumpy, unpredictable costs tied to clinical trials, staffing, and partnerships, making any single quarter hard to forecast. The analyst consensus estimate is also just a snapshot from market creation and could shift before August 2026. The earnings date is still well in the future, so a lot can change on the expense and revenue side between now and then.

The odds right now

• Will CRISPR Therapeutics (CRSP) beat quarterly earnings?54%

Price history

How this resolves

Resolves August 3, 2026

As of market creation, CRISPR Therapeutics is estimated to release earnings on August 3, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.18 as of market creation. Read the full resolution rules on the live market page.

Related

Same markets. A fraction of the fee.

These apps all route to the same exchange order book. The difference is what each one adds on top of the exchange's own fee.

Published rates, checked July 2026. MetaMask charges a flat 4 percent per prediction trade. Jupiter adds a fee equal to the exchange's own taker fee at fill time, roughly 2 to 4 percent at typical odds. Where a market carries an exchange settlement fee, it applies everywhere, whichever app you use. Paridesk adds nothing on maker orders.

Trade this market on Paridesk: non-custodial, 0.5% fee.